{
    "clinical_study": {
        "@rank": "146205", 
        "acronym": "OPTIMIZE", 
        "arm_group": {
            "arm_group_label": "Irritable Bowel Disease", 
            "description": "Infliximab administered according to current FDA and EMS approved doses and intervals."
        }, 
        "biospec_descr": {
            "textblock": "Whole Blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to develop a predictive model that will allow optimized dosing\n      of infliximab for individual patients"
        }, 
        "brief_title": "Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Crohn's Disease", 
            "Ulcerative Colitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Crohn Disease", 
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "The use of pharmacokinetic analyses incorporating relevant determinants of the infliximab\n      serum concentration can be used to develop a predictive model that will allow optimized\n      dosing for individual patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  a diagnosis of CD or UC by usual criteria,\n\n          -  moderate to severely active CD defined by a CDAI \u2265 220, with confirmed endoscopic\n             activity (CDEIS \u2265 6) or moderate to severely active UC, defined by a Mayo Score \u2265 6,\n             with a Mayo endoscopic subscore \u2265 2,\n\n          -  a need for  treatment with IFX for induction of remission as clinically indicated\n\n          -  patients previously exposed to adalimumab and/or certolizumab who are na\u00efve to\n             infliximab will be allowed to participate.\n\n        Exclusion Criteria:\n\n          -  perianal CD exclusively\n\n          -  disease limited to the rectum in patients with UC (i.e., disease must extend \u2265 15 cm\n             from the anal verge)\n\n          -  patients with known antibodies to IFX (ADAs) at baseline\n\n          -  a contraindication to infliximab therapy\n\n          -  a contraindication to endoscopy\n\n          -  an ostomy\n\n          -  planned surgery\n\n          -  evidence of severe or unstable hepatic, gastrointestinal, cardiovascular,\n             respiratory, neurological, psychiatric, hematological or renal disease at the\n             discretion of the investigator,\n\n          -  Pregnancy or breastfeeding,\n\n          -  treatment with any investigational drug in the past 30 days, or 5 half lives\n             (whichever is longer)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "50 patients with Crohn's Disease and 50 patients with Ulcerative Colitis from 10 centres\n        (Canada, United States, Netherlands and Spain)."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787786", 
            "org_study_id": "RP1207"
        }, 
        "intervention_browse": {
            "mesh_term": "Infliximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Crohn's Disease", 
            "Ulcerative Colitis", 
            "Optimal Use of infliximab"
        ], 
        "lastchanged_date": "December 9, 2013", 
        "number_of_groups": "1", 
        "official_title": "Defining and Predicting the Ideal Infliximab Pharmacokinetic Profile Associated With Treatment Efficacy in Patients With Inflammatory Bowel Disease", 
        "other_outcome": {
            "measure": "Identification of patients at baseline that would benefit from receiving higher does of infliximab due to accelerated drug clearance", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "overall_contact": {
            "email": "dking@robarts.ca", 
            "last_name": "Debra King", 
            "phone": "519-851-4610"
        }, 
        "overall_official": {
            "affiliation": "Robarts Clinical Trials - Western University", 
            "last_name": "Brian Feagan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration", 
                "Netherlands: Dutch Health Care Inspectorate", 
                "Spain: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to define the PK profile of IFX in patients with CD and UC and to determine covariates influencing drug clearance.", 
            "measure": "Pharmacokinetic Analysis of Infliximab in patients with moderate to severely active ulcerative colitis and Crohn's Disease", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "reference": [
            {
                "PMID": "16339095", 
                "citation": "Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76."
            }, 
            {
                "PMID": "12047962", 
                "citation": "Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541-9."
            }, 
            {
                "PMID": "21484965", 
                "citation": "Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb;18(2):201-11. doi: 10.1002/ibd.21697. Epub 2011 Apr 11."
            }, 
            {
                "PMID": "19174781", 
                "citation": "Gisbert JP, Pan\u00e9s J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009 Mar;104(3):760-7. doi: 10.1038/ajg.2008.88. Epub 2009 Jan 27. Review."
            }, 
            {
                "PMID": "16931170", 
                "citation": "Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006 Oct;4(10):1248-54. Epub 2006 Aug 22."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787786"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessment of  potential interactions between these determinants.", 
            "measure": "Quantification of relative strengths of individual determinants of infliximab pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "source": "University of Western Ontario, Canada", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Western Ontario, Canada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}